Its a chronic, relapsing condition, much like type 2 diabetes or hypertension
While these values appeared notable, they fell within the observed range of intersubject variability, which was determined as approximately 30%
Sources Food and Drug Administration (FDA): FDA Approves New Medication for Chronic Weight Management Molecular Metabolism Journal: Glucagon-like peptide 1 (GLP-1) American Gastroenterological Association (AGA): Biology of Incretins: GLP-1 and GIP Columbia Surgery: The Ozempic Effect: Everything You Need to Know About Medical Weight Loss Eli Lilly: Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies American Diabetes Association (ADA): Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Important Medical Information and Disclaimers Important Current Status Update : As of March 19, 2025, the FDA has ended enforcement discretion for compounded tirzepatide
Dont do this if youre injecting Lovenox
Zepbound is a significant addition to the arsenal of treatments for chronic weight management, garnering attention for its FDA-approved status in aiding obesity management